Use visual inspection within validation
Visual inspection alone is generally insufficient for cleaning validation.
CV-REQ-000005
EU GMP Annex 15: Qualification and Validation§ 10.2
TOPIC EXPLORER
Visual Inspection
Making visual cleanliness an explicit, reproducible part of the control strategy.
3 connected references
Justify the changeover control strategy
Reduced analytical testing requires robust justification, including visual-inspection capability.
CV-REQ-000023
HBEL and cross-contamination: questions and answers§ Q7–Q8
Evaluate visual inspection capability
Reliance on visual inspection needs evidence supporting the intended limit.
CV-REQ-000030
Cross-contamination control and HBEL Q&As§ Inspectorate commentary — visual inspection
Practical guidance
Visual Clean Is Important — but When Is It Enough?
Visual inspection was present in every one of the cleaning findings FDA issued between 2024 and 2026 — never as the accused technique, always as the whole of the evidence. The distinction between a qualified visual method and a visual-only release decision is the difference between a control and an assumption.
PIC/S Publishes PI 006-4: A New Qualification and Validation Recommendation Takes Effect in October
PIC/S has published PI 006-4, the revised Recommendations on Qualification and Validation, superseding the 2007 PI 006-3 and entering into force on 1 October 2026. Cleaning validation now occupies a full chapter, with HBEL-driven scope, explicit limits on visual inspection and a clear position against continued test-until-clean practice.
FDA Challenges a Visual-Only Cleaning Validation Strategy
A 2026 FDA warning letter to Dabur India rejects a shared-equipment cleaning programme that relied exclusively on visual inspection. The objection is narrower than it appears — and it turns on missing quantitative limits, not on visual inspection itself.
What FDA Has Been Citing in Cleaning Validation: The Recurring Themes of 2025–2026
Twelve FDA warning letters issued between 3 December 2024 and 24 July 2026 cite cleaning and cross-contamination control. Read together rather than case by case, they stop looking like twelve incidents and start looking like one audit checklist: worst-case selection, hold times, recovery, MACO justification, visual-only strategies, sampling locations, change control and lifecycle management — in that order of frequency.
Worst Case or Product-Specific? New Research Reopens the Cleaning Validation Strategy Debate
A comparative review in the PDA Journal weighs worst-case matrices against product-specific validation and proposes a hybrid model anchored on visible residue limits.
Released as Clean, Yet Residue Remained: A Simple Finding With a Bigger System Lesson
An FDA investigator found white residue inside Tank #68 at Chemco Corporation — equipment the quality unit had already verified as clean. The finding itself is mundane. What it exposes about release decisions, shared equipment and the absence of cleaning validation is not.
EU and PIC/S Start the Next Revision of Annex 15 — What Validation Teams Should Watch
A joint EMA–PIC/S concept paper proposes extending Annex 15 to active substance manufacturers and aligning it with ICH Q9(R1). The current Annex 15 stays in force, and the earliest a revised text could be published is 2028.
Do Cleaning Validation Programmes Need Every Analytical Test They Currently Run?
A lightning talk at PDA Week 2025 argued for a lean approach to analytical panels in cleaning validation. The independent framework to justify it already exists in ASTM E3106 and ICH Q9(R1) — but only if the arithmetic is documented.
What Does 'Clean' Mean When Equipment Status and Physical Condition Disagree?
A March 2025 FDA warning letter to Aspen Biopharma Labs Private Limited records investigators finding manufacturing equipment labelled "Cleaned" while liquid with a floating substance or residue remained on product-contact surfaces. That gap between a status tag and physical reality is one of the most consequential — and most preventable — failures in cleaning validation.
Visual Inspection Alone Was Not Enough: What FDA Expected to See
In Warning Letter 320-25-38 the FDA did not attack visual inspection as a technique. It objected to a cleaning programme in which visual inspection was the only evidence on the table — no acceptance criteria for carryover residues, no analytical data, and no procedures for the rest of the equipment train.
When Shared Equipment Has Never Been Cleaning-Validated: Lessons From an FDA Warning Letter
An FDA Warning Letter to Indian API manufacturer Micro Orgo Chem describes non-dedicated equipment that had never been cleaned under a validated procedure, cleaning SOPs that were not followed, and no evidence that the rinse and swab samples required by the firm's own procedure were ever collected or tested.